---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097555"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:55:47.554656+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results

## Summary
- Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
- Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).
- FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.
- Cash $514.4M provides runway into 2028.
- Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28.

## SEC filing metadata
- accession: 0001193125-26-097555
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/0001193125-26-097555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097555
- JSON: https://secwatch.observer/filing/0001193125-26-097555.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097555.txt

## Key facts
- Earnings Releases
  Dianthus Therapeutics, Inc. /DE/ reported the fourth quarter and full year ending December 31, 2025 results: net income $162.3 million or $4.20 per share, EPS $4.20 per share.
  - Period: the fourth quarter and full year ending December 31, 2025
  - Net income: $162.3 million or $4.20 per share
  - EPS: $4.20 per share
  - Result: reported results
  source text: On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/0001193125-26-097555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.